Skip to main content

Dr. Stephen L. Tam, MD

Internal Medicine (Internal Medicine Physician)

  • Medicare participating

At a glance

Years since graduation
25
In the NPI registry since
2006
Medicare patients seen, 2024
248

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Internal Medicine Physician primary
    NV license 12069

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Internal Medicine per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
248
Services billed
14,074
Patients’ average age
66
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes2,251120
Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes60979
Therapy procedure to re-educate brain-to-nerve-to-muscle function, each 15 minutes44239
Application of electrical stimulation with therapist present, each 15 minutes44239
Biofeedback training21515
Application of blood vessel compression device15625
Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes145112
Therapy procedure using exercise to develop strength, endurance, range of motion, and flexibility, each 15 minutes13715
Therapy procedure using manual technique, each 15 minutes13315
Training for self-care or home management, each 15 minutes13215

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $219 in total to this clinician.

By type
Travel and Lodging$219

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Aug 29, 2025E.r. Squibb & Sons, L.l.c.
Aug 29, 2025
Travel and Lodging
travel to Atlanta, GA · in-kind
$219

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Nevada →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $644,399 in research payments for these studies, mostly to the institutions running them.

  • A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
    ModernaTX, Inc. · Active, not recruiting · NCT06592794
  • Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
    Teva Pharmaceuticals USA, Inc.
  • A Phase 3b, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Laparoscopic Procedures of the Intraperitoneal or Retroperitoneal Cavi…
    Vertex Pharmaceuticals Incorporated
  • UC P3: Double-Blind Treat Straight Through
    F. Hoffmann-la Roche AG
  • A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
    Genentech, Inc.
  • A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
    F. Hoffmann-la Roche AG
  • UC P3: Double-Blind Treat Straight Through
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Internal Medicine clinicians in Las Vegas

Sources

NPI registry (CMS NPPES, November 2026; record last updated December 13, 2007), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1689738478. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.